The tweet was deleted by the author.
But we saved everything 🙂.
Cullinan Therapeutics has introduced a new biomarker-driven approach aimed at elucidating immune reset mechanisms in autoimmune diseases, according to a MassBio article.
Chief Scientific Officer Jennifer Michaelson, PhD, and Vice President of Translational Research Irina Shapiro, PhD, presented the strategy, emphasizing how it could advance the understanding and treatment of autoimmune conditions. The company’s latest efforts reflect ongoing innovation in translational research methods focused on improving clinical outcomes for patients with immune disorders.
Cullinan Therapeutics previously pursued T cell engager therapies targeting B cells to address the root causes of autoimmune diseases, as detailed in earlier research initiatives. The company also released initial clinical data for its investigational T cell engager CLN-978 in systemic lupus erythematosus and rheumatoid arthritis at EULAR2026, according to presentations on its clinical programs. These efforts reflect Cullinan's ongoing focus on innovative approaches in the autoimmune space.